Personalis Price to Sales Ratio 2018-2025 | PSNL
Historical PS ratio values for Personalis (PSNL) over the last 10 years. The current P/S ratio for Personalis as of April 14, 2026 is .
| Personalis P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-04-15 | 6.63 | 8.42 | |
| 2025-12-31 | 7.96 | $0.79 | 10.11 |
| 2025-09-30 | 6.52 | $0.88 | 7.44 |
| 2025-06-30 | 6.56 | $1.13 | 5.78 |
| 2025-03-31 | 3.51 | $1.37 | 2.56 |
| 2024-12-31 | 5.78 | $1.52 | 3.80 |
| 2024-09-30 | 5.38 | $1.65 | 3.27 |
| 2024-06-30 | 1.17 | $1.60 | 0.73 |
| 2024-03-31 | 1.49 | $1.52 | 0.98 |
| 2023-12-31 | 2.10 | $1.54 | 1.37 |
| 2023-09-30 | 1.21 | $1.49 | 0.81 |
| 2023-06-30 | 1.88 | $1.44 | 1.30 |
| 2023-03-31 | 2.76 | $1.49 | 1.85 |
| 2022-12-31 | 1.98 | $1.43 | 1.39 |
| 2022-09-30 | 2.97 | $1.53 | 1.94 |
| 2022-06-30 | 3.45 | $1.71 | 2.02 |
| 2022-03-31 | 8.19 | $1.80 | 4.54 |
| 2021-12-31 | 14.27 | $1.96 | 7.29 |
| 2021-09-30 | 19.24 | $2.07 | 9.28 |
| 2021-06-30 | 25.30 | $2.13 | 11.86 |
| 2021-03-31 | 24.61 | $2.25 | 10.92 |
| 2020-12-31 | 36.61 | $2.37 | 15.44 |
| 2020-09-30 | 21.67 | $2.79 | 7.76 |
| 2020-06-30 | 12.97 | $2.78 | 4.66 |
| 2020-03-31 | 8.07 | $4.57 | 1.77 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |